Akeso’s innovative PD-1 x VEGF bispecific antibody, ivonescimab, has secured a significant second Phase III triumph, demonstrating superior overall survival (OS) in frontline, advanced biliary tract cancer (BTC) within a Chinese study. This latest success, following a previous win in non-small cell lung cancer (NSCLC), significantly strengthens Summit Therapeutics’ substantial investment in the drug and positions ivonescimab for a promising global rollout across a spectrum of solid tumour indications.
The HARMONi-GI1 study, conducted by Akeso, has provided compelling evidence that the combination of ivonescimab and chemotherapy significantly outperforms the current standard of care (SoC) in patients with advanced BTC. This marks a pivotal moment for the bispecific antibody, extending its demonstrated efficacy beyond its initial indications and validating the strategic foresight of Summit Therapeutics’ $500 million upfront investment in Akeso’s groundbreaking therapy.
A Pivotal Breakthrough in Biliary Tract Cancer Treatment
The HARMONi-GI1 study (NCT06591520) enrolled patients with advanced biliary tract cancer across multiple centres in China. The trial design pitted a combination therapy of ivonescimab and chemotherapy against a regimen comprising AstraZeneca’s Imfinzi (durvalumab) plus chemotherapy. Biliary tract cancer, a notoriously aggressive and often late-diagnosed malignancy, currently sees its standard of care revolve around chemotherapy agents such as gemcitabine and cisplatin, often in conjunction with immune checkpoint inhibitors like Imfinzi or MSD’s Keytruda (pembrolizumab).
The results, derived from a pre-specified interim analysis, revealed a statistically significant improvement in overall survival (OS) for patients treated with the ivonescimab-based regimen. This achievement not only marks a crucial victory for ivonescimab but also directly challenges and surpasses one of the established standard-of-care options in BTC, thereby meeting the trial’s primary endpoint with resounding success.
Beyond the critical improvement in OS, the ivonescimab and chemotherapy combination demonstrated significant gains in key secondary endpoints. Progression-free survival (PFS), a measure of how long patients live without their cancer worsening, also showed substantial improvement. Furthermore, the objective response rates (ORR), indicating the percentage of patients whose tumors shrink or disappear, were notably enhanced with the ivonescimab combination. These comprehensive positive results underscore the drug’s broad therapeutic potential in this challenging cancer type. Akeso and Summit Therapeutics anticipate presenting detailed findings from the HARMONi-GI1 study at an upcoming major medical conference, offering the global oncology community an in-depth look at this promising data.
Ivonescimab’s Expanding Global Footprint and Summit Therapeutics’ Strategic Vision
The Phase III success in biliary tract cancer represents ivonescimab’s first demonstrated efficacy in a gastrointestinal oncology indication. This achievement is particularly significant as it broadens the perceived therapeutic landscape for the bispecific antibody, suggesting its potential to address a wider array of solid tumours beyond its initial regulatory approval in non-small cell lung cancer (NSCLC) in China.
Summit Therapeutics, the licensor of ivonescimab for major global markets, is actively engaged in pursuing regulatory approval for the drug in the United States. The U.S. Food and Drug Administration (FDA) is currently reviewing ivonescimab for its potential use in NSCLC, with a decision on its future in the U.S. market eagerly awaited. This latest clinical success story provides a powerful impetus for that regulatory review and strengthens Summit’s case for bringing this innovative therapy to patients in the U.S. and beyond.
The substantial upfront investment made by Summit Therapeutics in 2022, totaling up to $5 billion to Akeso for the rights to ivonescimab across the U.S., Europe, Canada, Japan, Latin America, the Middle East, and Africa, is now appearing increasingly well-placed. This strategic bet is being validated by successive clinical triumphs, painting a picture of a highly promising future for the drug.
Since securing the licensing agreement, Summit Therapeutics has been diligently progressing ivonescimab through a robust global development program. This includes initiating several frontline studies across various subsets of NSCLC, a clear indication of the company’s commitment to maximizing the drug’s impact in this prevalent cancer. Furthermore, ivonescimab is being investigated in head and neck squamous cell carcinoma (HNSCC) and colorectal cancer, further demonstrating its potential across diverse solid tumour types.
Akeso is also spearheading the evaluation of ivonescimab in several other challenging solid tumour indications through mid-to-late-stage clinical trials. These ongoing investigations include studies in ovarian cancer and triple-negative breast cancer, two forms of cancer with significant unmet needs. Additionally, the drug is being explored for its efficacy in hepatocellular carcinoma, the most common type of liver cancer. This multi-pronged approach underscores the perceived versatility of ivonescimab’s mechanism of action, targeting both immune evasion and tumor angiogenesis.
A Novel Mechanism of Action Driving Broad Efficacy
Ivonescimab’s therapeutic potential stems from its innovative bispecific antibody design. It simultaneously targets programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF). The PD-1 pathway is a critical regulator of the immune system, and its blockade can unleash T-cells to attack cancer cells. VEGF, on the other hand, plays a crucial role in tumor angiogenesis – the process by which tumors develop new blood vessels to fuel their growth and spread. By inhibiting both PD-1 and VEGF, ivonescimab offers a dual-action approach that can potentially enhance anti-tumor immunity while simultaneously starving the tumor of its blood supply. This synergistic mechanism is believed to be a key driver of its observed efficacy across different tumor types.
Market Projections and the Future of Bispecific Antibodies
The consistent positive clinical data emerging from ivonescimab’s development pipeline has generated significant optimism within the pharmaceutical industry. According to a consensus forecast from GlobalData, the parent company of Clinical Trials Arena, ivonescimab is projected to achieve mega-blockbuster status by 2032, with anticipated sales exceeding $9 billion. This projection underscores the immense market potential of this bispecific antibody and highlights the growing importance of this class of therapeutics in oncology.
The success of ivonescimab also signals a broader trend towards the development and adoption of bispecific antibodies in cancer treatment. These complex molecules offer the potential for enhanced efficacy and targeted action by engaging multiple biological pathways simultaneously. As research and development in this area continue to advance, bispecific antibodies are poised to play an increasingly vital role in the fight against cancer, offering new hope and improved outcomes for patients facing a wide range of malignancies.
The ongoing global clinical trials for ivonescimab across various solid tumour indications, coupled with its current U.S. regulatory review for NSCLC, represent a critical juncture for both Akeso and Summit Therapeutics. The second major Phase III win in biliary tract cancer not only validates the scientific rationale behind the drug’s dual-action mechanism but also significantly de-risks Summit’s substantial investment. As more data emerges from ongoing studies, the full therapeutic potential of ivonescimab is expected to be further elucidated, potentially revolutionizing treatment paradigms for numerous cancer types and solidifying its position as a leading therapy in the evolving landscape of immuno-oncology.
About the Author
